Related Experiment Video
Updated: Sep 18, 2025
07:42
Nerve-sparing Mid-urethral Obstruction NeMO in Female Small Rodents
Published on: April 25, 2017
9.7K
Off-Label but On-Target: Sacral Neuromodulation for Neurogenic Bladder Dysfunction.
Keianna Vogel1, Nissrine Nakib2
1Department of Urology, University of Minnesota, Minneapolis, 420 Delaware St SE, MMC 394, MN, 55455, USA.
Current Urology Reports
|June 23, 2025
Summary
Sacral neuromodulation (SNM) shows promise for neurogenic bladder dysfunction (NBD) in patients unresponsive to standard treatments. This minimally invasive therapy can improve bladder symptoms and function, offering a new management option.
Area of Science:
- Neurology
- Urology
- Biomedical Engineering
Background:
- Neurogenic bladder dysfunction (NBD) is a common complication of various neurological disorders.
- Management of NBD is challenging, particularly for patients refractory to conventional therapies.
Purpose of the Study:
- To review the emerging role of sacral neuromodulation (SNM) as an off-label treatment for neurogenic bladder dysfunction.
- To explore the efficacy and potential of SNM in managing refractory NBD.
Main Methods:
- Review of recent studies, case series, and retrospective analyses on SNM for NBD.
- Examination of technological advancements in SNM devices.
Main Results:
- SNM demonstrated improvements in lower urinary tract symptoms, bladder storage, and emptying in select NBD patients.
- Evidence suggests reduced reliance on catheterization and medication with SNM.
- Technological innovations are expanding the clinical applicability of SNM.
Conclusions:
- Sacral neuromodulation is an emerging, minimally invasive treatment for neurogenic bladder dysfunction.
- Careful patient selection and understanding of pathophysiology are crucial for successful SNM outcomes.
- Continued evidence and device innovation may significantly alter NBD management strategies.
Related Concept Videos
01:26The Micturition Reflex
1.1K
Urination, or micturition involves the coordination of the bladder's detrusor muscle and two sphincters to ensure controlled bladder emptying.
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating...
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating...
1.1K
01:23Urinary Bladder
1.6K
The urinary bladder is a hollow, muscular sac that temporarily stores urine before it is expelled from the body. It can hold approximately 600 mL of urine prior to micturition. The bladder is retroperitoneal and located behind the pubic symphysis in the pelvic floor.
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
1.6K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
313
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
313